Replies to post #97527 on Biotech Values

[genisi]

Re Oppenheimer MS survey

73% of neurologists thought use of Copaxone could
decrease. On ave. Copaxone use could decline by 18.6% if gilenia is approved. They estimate Teva's 2011 EPS could drop 6.5% if gilenia is approved.